Innovent Biologics Presents Positive Clinical Results for Efdamrofusp Alfa and IBI324 at AAO
Innovent Biologics, Inc. (HKG: 1801), a China-based biopharmaceutical company, has published the latest clinical results...
CSPC Pharmaceutical Group Gets NMPA Approval for SYS6011 Biologic Drug Clinical Study
CSPC Pharmaceutical Group Ltd (HKG: 1093), a China-based pharmaceutical company, has announced that it has...
Bayer Extends Collaboration with Broad Institute to 2028 for Oncology Drug Targets and Therapies
Germany’s Bayer (NYSE: ETR) has announced the extension of its 2013 collaboration agreement with the...
AbbVie Secures Option Agreement with Aldeyra Therapeutics for RASP Modulator Reproxalap
AbbVie (NYSE: ABBV) has entered into an option agreement with Aldeyra Therapeutics (NASDAQ: ALDX), a...
Novo Nordisk Reports 33% YOY Growth in Q3 2023 with Diabetes and Obesity Care Driving Sales
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has released its Q3 2023 earnings report, showcasing...
Cutia Therapeutics Achieves Primary Endpoint in Phase I Study of CU-40101 for Androgenic Alopecia
Cutia Therapeutics (HKG: 2487), a company specializing in dermatological therapies, has announced that its Phase...
Sanofi Regains Exclusive Rights to Rezurock in China, Terminating Agreement with BioNova and BK Pharmaceuticals
BioNova Pharmaceuticals, a Shanghai-based oncology-focused biopharmaceutical company founded in 2018, and Sanofi (NASDAQ: SNY), a...
Innovent Biologics Reports Q3 2023 Sales Exceeding RMB 1.6 Billion with 45% YOY Growth
Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced its...
Amoy Diagnostics Receives NMPA Approval for MSI Detection Kit as Companion Diagnostic for Immunotherapy
Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a prominent player in the Chinese diagnostics industry,...
Gaush Meditech Ltd Receives NMPA Approval for Rigid Corneal Contact Lens
Gaush Meditech Ltd (HKG: 2407), a company based in Suzhou, has announced that it has...
Wuhan Hiteck Biological Pharma Receives NMPA Approval for Aponermin in Multiple Myeloma Treatment
Wuhan Hiteck Biological Pharma Co., Ltd (SHE: 300683), a Chinese biopharmaceutical company, has announced that...
Abbisko Therapeutics to Present CSF-1R Inhibitor ABSK021 Data at CTOS Annual Meeting
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it will present data...
Ascentage Pharma’s Olverembatinib Showcases Promising Results at ASH Annual Meeting
Suzhou-based Ascentage Pharma (HKG: 6855) has presented the latest results of multiple studies regarding its...
Sino Medical Sciences Technology Secures TFDA Approval for HT Supreme Drug-Eluting Stent System
Sino Medical Sciences Technology Inc., (SHA: 688108), a Chinese medical technology company, has announced that...
Shanghai Pharmaceuticals Gets NMPA Approval for Phase I Clinical Study of B019 CAR-T Cell Injection
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company in China, has...
I-Mab and HI-Bio’s Felzartamab Earns Breakthrough Therapy Designation from US FDA
China-based I-Mab (NASDAQ: IMAB) and its US partner HI-Bio have announced that they have received...
Eli Lilly & Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances
Eli Lilly & Co., (NYSE: LLY) has announced its financial results for the third quarter...
Organon Reports Q3 2023 Financials with Mixed Results, Notable Decline in Women’s Health Sales
US-based Organon (NYSE: OGN) has released its financial results for the third quarter of 2023,...
Pfizer Inc. Reports Q3 2023 Revenue Contraction and Launches Cost Realignment Program
US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the third...
AstraZeneca Partners with Cellectis for Next-Generation Cell and Gene Therapies
UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced a strategic partnership with Cellectis (EPA:...